Use of intravenous immune globulin and rituximab for desensitization of highly human leukocyte antigen-sensitized patients awaiting kidney transplantation.
Rehman
Shehzad
S
Meier-Kriesche
Herwig-Ulf
HU
Scornik
Juan
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D003888:Desensitization, Immunologic / Q000379:methods*; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D000069283:Rituximab; D014850:Waiting Lists
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D006680:HLA Antigens; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D000069283:Rituximab